Fresenius stock after-hours at EUR 43.86: plus 0.41 percent versus Lang & Schwarz prior close

Fresenius stock was at EUR 43.86 after-hours at 5:51 p.m. CEST on October 5, 2026, up 0.41 percent versus the Lang & Schwarz prior close. Fresenius also completed its mAbxience acquisition.

Fresenius stock was at EUR 43.86 after-hours at 5:51 p.m. CEST on October 5, 2026. The price was up 0.41 percent versus the Lang & Schwarz prior close of EUR 43.68.

After-hours trading on October 5, 2026

The latest Lang & Schwarz quote showed a bid of EUR 43.72 and an ask of EUR 44.00. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Fresenius stock.

Fresenius takes full ownership of mAbxience

In an investor news release dated October 1, 2026, Fresenius SE & Co. KGaA said it had acquired the remaining 45 percent of mAbxience Holding S.L. from Insud Pharma S.L. and Invim Corporativo S.L. for total consideration of up to EUR 750 million, including a contingent EUR 50 million payment upon site approvals. The transaction was signed and completed on September 30, 2026, without regulatory approvals.

Fresenius said the acquisition makes mAbxience wholly owned within Fresenius Kabi’s Biopharma business. The company expects the transaction to be immediately accretive to Group core earnings per share and said its full-year 2026 guidance and 2030 Biopharma ambition were unchanged.